Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading: A Meta-analysis.

Aristeidis H Katsanos, George A Alexiou, Andreas D Fotopoulos, Pascal Jabbour, Athanasios P Kyritsis, Chrissa Sioka

Journal: Clinical nuclear medicine 2019;44(11):864-869

PMID: 31205150

Abstract

PURPOSE

Gliomas constitute the most frequent primary brain tumors. Glioblastoma, the most common and malignant glioma in adults, has dismal prognosis with any current therapy. On the other hand, low-grade gliomas, the second most common type of gliomas, are potentially curative with appropriate treatment.

METHODS

We conducted a meta-analysis to assess the performance of PET tracers with the best available evidence, namely, fluorodeoxyglucose (FDG), C-methionine (MET), and F-fluoroethyltyrosine (FET), in differentiating low- from high-grade gliomas.

RESULTS

Twenty-three studies with a total of 994 participants were included in this meta-analysis. The pooled sensitivities of both MET PET and FET PET were found to be significantly higher than of FDG PET (94%, 88%, and 63% respectively, P < 0.001). The pooled specificity of FDG PET was found to be significantly greater compared with both MET PET and FET PET (89%, 55%, and 57%, respectively; P = 0.002). Fluorodeoxyglucose PET was superior in terms of higher positive likelihood ratio values compared with both FET PET and MET PET.

CONCLUSIONS

This meta-analysis indicated that both MET and FET were superior to FDG in terms of sensitivity for identifying glioma grade.

Address: From the Department of Neurology, St. Josef Hospital, Ruhr University of Bochum, Bochum, Germany.; Neurosurgical Research Institute, University of Ioannina.; Departments of Neurosurgery.; Nuclear Medicine, University of Ioannina School of Medicine, Ioannina, Greece.; Division of Neurovascular Surgery and Endovascular Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA.; Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.